Viewing Study NCT04489433

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:48 AM
Ignite Modification Date: 2026-01-09 @ 9:44 AM
Study NCT ID: NCT04489433
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2025-12-18
First Post: 2020-07-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic melanoma View
None Melanoma View
None Stage IV melanoma View
None Cutaneous View
None Mucosal View
None Ocular View
None Dabrafenib View
None Trametinib View
None DRB436 View
None TMT212 View
None Compassionate Use View
None Cohort View
None Expanded access View